Research & Regulatory News

How NICE Decides Whether the NHS Funds a Medicine

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

An MHRA marketing authorisation establishes that a medicine is safe, effective and of adequate quality. It says nothing about whether the NHS will pay for it. That is decided separately by NICE, which assesses cost-effectiveness, and for obesity medicines the size of the eligible population makes those appraisals unusually difficult.

Key facts

MHRA decides
Safety, efficacy, quality (the licence)
NICE decides
Cost-effectiveness (NHS funding)
Common metric
Cost per quality-adjusted life year (QALY)
Obesity-specific difficulty
Very large eligible population
Typical outcome
Restricted eligibility or managed access
Orforglipron guidance
Expected 27 January 2027 (first due 18 November 2026)

Two decisions, two bodies, two questions

The MHRA asks whether a medicine works and is safe enough to be sold. NICE asks whether the health benefit it delivers justifies its cost relative to everything else the NHS could spend that money on. A medicine can pass the first comfortably and fail the second, and the gap between the two decisions is often a year or more.

What a QALY is and why it governs the outcome

NICE appraisals are built on cost per quality-adjusted life year, a measure combining how long a treatment extends life with how much it improves the quality of that life. A threshold range is applied as a guide rather than a hard rule. The calculation depends heavily on modelled long-term outcomes, which is where obesity medicines become contentious. The benefit accrues over decades and has to be projected rather than observed.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why obesity medicines are hard appraisals

The eligible population is enormous. A medicine licensed for BMI of 30 or above, or 27 to 30 with a comorbidity, potentially applies to millions of people in England alone. Even a modest cost per patient becomes a very large aggregate budget impact, and budget impact is assessed separately from cost-effectiveness. This is why previous incretin appraisals have produced tightly restricted eligibility, specialist-service requirements or managed-access agreements rather than open prescribing.

The discontinuation problem inside the model

Cost-effectiveness modelling has to account for what happens when treatment stops, and the evidence there is unambiguous: substantial regain follows cessation across the class. A model assuming sustained benefit after stopping produces a very different answer from one assuming most of the reduction is lost. This is one reason maintenance-dosing trial data matter to funding decisions as much as to clinicians.

What to expect next

Guidance on orforglipron was due on 18 November 2026. After a second committee meeting on 10 November 2026, NICE moved the expected date to 27 January 2027. Possible outcomes range from a recommendation with restricted eligibility, through managed access, to a negative recommendation. A positive recommendation does not produce immediate prescribing either. Implementation follows, so NHS prescribing would start some time after the guidance even in the favourable case.

Frequently asked questions

If the MHRA approved it, why will the NHS not prescribe it?

Because those are different questions. The MHRA licenses on safety and efficacy; NICE decides funding on cost-effectiveness, in a separate appraisal that comes afterwards.

What is a QALY?

A quality-adjusted life year, combining length and quality of life into one measure so treatments across different conditions can be compared on cost per unit of benefit.

Does a positive NICE recommendation mean immediate availability?

No. Implementation follows the recommendation, and obesity medicines have typically come with eligibility restrictions and service requirements.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.